经颅交流电刺激治疗脊髓小脑性共济失调3型：一项随机对照试验。

IF 11.7 1区医学 Q1 CELL BIOLOGY

Cell Reports Medicine Pub Date : 2025-06-17 DOI:10.1016/j.xcrm.2025.102162

Xinyuan Chen, Xia Liu, Wei Lin, Lin Zhang, Xiaoping Cheng, Ziqiang Huang, Wanli Zhang, Huating Zeng, Yanhua Lian, Yingjuan Zhang, Mengcheng Li, Naping Chen, Shuna Huang, Zhaodi Wang, Xichen Wang, Zhenyi Liu, Ruying Yuan, Xuanyu Chen, Zhixian Ye, Bi Cheng, Yue Zhang, Qunlin Chen, Duolao Wang, Jun Ni, Ning Wang, Ying Fu, Shirui Gan

{"title":"经颅交流电刺激治疗脊髓小脑性共济失调3型：一项随机对照试验。","authors":"Xinyuan Chen, Xia Liu, Wei Lin, Lin Zhang, Xiaoping Cheng, Ziqiang Huang, Wanli Zhang, Huating Zeng, Yanhua Lian, Yingjuan Zhang, Mengcheng Li, Naping Chen, Shuna Huang, Zhaodi Wang, Xichen Wang, Zhenyi Liu, Ruying Yuan, Xuanyu Chen, Zhixian Ye, Bi Cheng, Yue Zhang, Qunlin Chen, Duolao Wang, Jun Ni, Ning Wang, Ying Fu, Shirui Gan","doi":"10.1016/j.xcrm.2025.102162","DOIUrl":null,"url":null,"abstract":"There are no specific treatments for spinocerebellar ataxia type 3 (SCA3), a neurodegenerative disease causing cerebellar dysfunction. Transcranial alternating current stimulation (tACS) can improve cerebellar motor functions, and it has been shown to be safe and effective in treating neurological diseases. This randomized controlled trial (RCT) explored the effects of tACS on SCA3 patients. Participants received either 40-min, 70 Hz, 2 mA tACS or sham stimulation daily for 2 weeks. The primary outcome was met by 80% of the active-tACS group (32/40) and 10% of the sham group (4/40). The active group also showed significantly greater reductions in the Scale for Assessment and Rating of Ataxia (SARA) scores. No serious adverse events occurred, indicating high safety. Therefore, tACS is effective, safe, and feasible for treating SCA3. The study is registered at ClinicalTrials.gov (NCT05557786).","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":"6 6","pages":"102162"},"PeriodicalIF":11.7000,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Transcranial alternating current stimulation for treating spinocerebellar ataxia type 3: A randomized controlled trial.\",\"authors\":\"Xinyuan Chen, Xia Liu, Wei Lin, Lin Zhang, Xiaoping Cheng, Ziqiang Huang, Wanli Zhang, Huating Zeng, Yanhua Lian, Yingjuan Zhang, Mengcheng Li, Naping Chen, Shuna Huang, Zhaodi Wang, Xichen Wang, Zhenyi Liu, Ruying Yuan, Xuanyu Chen, Zhixian Ye, Bi Cheng, Yue Zhang, Qunlin Chen, Duolao Wang, Jun Ni, Ning Wang, Ying Fu, Shirui Gan\",\"doi\":\"10.1016/j.xcrm.2025.102162\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"There are no specific treatments for spinocerebellar ataxia type 3 (SCA3), a neurodegenerative disease causing cerebellar dysfunction. Transcranial alternating current stimulation (tACS) can improve cerebellar motor functions, and it has been shown to be safe and effective in treating neurological diseases. This randomized controlled trial (RCT) explored the effects of tACS on SCA3 patients. Participants received either 40-min, 70 Hz, 2 mA tACS or sham stimulation daily for 2 weeks. The primary outcome was met by 80% of the active-tACS group (32/40) and 10% of the sham group (4/40). The active group also showed significantly greater reductions in the Scale for Assessment and Rating of Ataxia (SARA) scores. No serious adverse events occurred, indicating high safety. Therefore, tACS is effective, safe, and feasible for treating SCA3. The study is registered at ClinicalTrials.gov (NCT05557786).\",\"PeriodicalId\":9822,\"journal\":{\"name\":\"Cell Reports Medicine\",\"volume\":\"6 6\",\"pages\":\"102162\"},\"PeriodicalIF\":11.7000,\"publicationDate\":\"2025-06-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cell Reports Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.xcrm.2025.102162\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CELL BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cell Reports Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.xcrm.2025.102162","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CELL BIOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

脊髓小脑性共济失调3型（SCA3）是一种导致小脑功能障碍的神经退行性疾病，目前尚无特异性治疗方法。经颅交流电刺激（tACS）可改善小脑运动功能，是一种安全有效的神经系统疾病治疗方法。这项随机对照试验（RCT）探讨了tACS对SCA3患者的影响。参与者每天接受40分钟，70 Hz， 2 mA的tACS或假刺激，持续2周。active-tACS组达到80% (32/40)，sham组达到10%（4/40）。运动组在共济失调评定量表（SARA）得分上也有明显更大的下降。未发生严重不良事件，安全性高。因此，tACS治疗SCA3是有效、安全、可行的。该研究已在ClinicalTrials.gov注册（NCT05557786）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Transcranial alternating current stimulation for treating spinocerebellar ataxia type 3: A randomized controlled trial.

There are no specific treatments for spinocerebellar ataxia type 3 (SCA3), a neurodegenerative disease causing cerebellar dysfunction. Transcranial alternating current stimulation (tACS) can improve cerebellar motor functions, and it has been shown to be safe and effective in treating neurological diseases. This randomized controlled trial (RCT) explored the effects of tACS on SCA3 patients. Participants received either 40-min, 70 Hz, 2 mA tACS or sham stimulation daily for 2 weeks. The primary outcome was met by 80% of the active-tACS group (32/40) and 10% of the sham group (4/40). The active group also showed significantly greater reductions in the Scale for Assessment and Rating of Ataxia (SARA) scores. No serious adverse events occurred, indicating high safety. Therefore, tACS is effective, safe, and feasible for treating SCA3. The study is registered at ClinicalTrials.gov (NCT05557786).

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cell Reports Medicine Biochemistry, Genetics and Molecular Biology-Biochemistry, Genetics and Molecular Biology (all)

CiteScore

15.00

自引率

1.40%

发文量

231

审稿时长

40 days

期刊介绍： Cell Reports Medicine is an esteemed open-access journal by Cell Press that publishes groundbreaking research in translational and clinical biomedical sciences, influencing human health and medicine. Our journal ensures wide visibility and accessibility, reaching scientists and clinicians across various medical disciplines. We publish original research that spans from intriguing human biology concepts to all aspects of clinical work. We encourage submissions that introduce innovative ideas, forging new paths in clinical research and practice. We also welcome studies that provide vital information, enhancing our understanding of current standards of care in diagnosis, treatment, and prognosis. This encompasses translational studies, clinical trials (including long-term follow-ups), genomics, biomarker discovery, and technological advancements that contribute to diagnostics, treatment, and healthcare. Additionally, studies based on vertebrate model organisms are within the scope of the journal, as long as they directly relate to human health and disease.